Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jun 09, 2022 10:47am
145 Views
Post# 34743521

RE:RE:RE:Extended private placement another 30 days

RE:RE:RE:Extended private placement another 30 days Why would you buy shares on this Private Placement at $.18 when you can buy shares on the open market for $.13 - $.15 ?   You get a 1/2 warrant per share at $.40...is that enough of an inducement ?  I say no.  Is anyone here on Stockhouse buying shares presently ?   Is it enough that Andrew Schutte is buying millions of shares ?   For me I need some solid evidence that Replicel is heading in the right direction.  If they were to give me some type of encouraging updateIi might  buy some more shares.
For me there are too many questions about the Dermal Injector.  What is causing the delay in seeking FDA Approval ?  Obviously something has caused the delay.....what is it ?
For the Shiseido Arbitration if Shiseido was willing to make an out of court (arbitration) settlement it would have happened by now. It looks like they have stonewalled Replicel and are going to leave it in the hands of the arbitrator.  
With that in mind I am not buying anymore shares presently.
<< Previous
Bullboard Posts
Next >>